Jagsonpal Pharmaceuticals Ltd reports Q2FY27 consolidated revenue of ₹96.4 crore, up 29% YoY, and net profit of ₹12.3 crore
- Consolidated EBITDA margin was 19.3%; standalone revenue rose 9.3% YoY to ₹81.4 crore, with a 22.7% EBITDA margin.
- Standalone EBITDA increased 2.5% YoY; net profit was ₹12.6 crore, up 0.1% YoY.
- Q2 included a ₹2 million exceptional expense related to the Aequitas acquisition.